Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Stomach Neoplasms 1Sarcoma, Myeloid 1Recurrence 1Pancreatic Ductal Adenocarcinoma 1Ovarian Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1Burkitt Lymphoma 1Breast Neoplasms 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

titanium silicide 1mitazalimab 1irinotecan sucrosofate 1devimistat 1S 1 (combination) 1PEGPH20 1Oxaliplatin 1Irinotecan 1Gemcitabine 1Escitalopram 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Pancreatic Ductal Adenocarcinoma × devimistat × Clear all
NCT03374852 2025-04-29

CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer

Thomas Jefferson University

Phase 2 Withdrawn
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡